
Elevation Oncology (ELEV) Stock Forecast & Price Target
Elevation Oncology (ELEV) Analyst Ratings
Bulls say
Elevation Oncology Inc is noted for its promising candidate EO-3021, an antibody-drug conjugate designed for treating a variety of solid tumors, showing a noteworthy objective response rate of 43% in a selected patient population. The anticipated upcoming data releases, specifically additional monotherapy results in Q2 2025 and combination therapy results in late 2025 to early 2026, are expected to bolster investor confidence, potentially facilitating access to further capital. Moreover, the innovative combination therapy strategies involving EO-3021 with other agents like dostarlimab and ramucirumab may enhance treatment profiles, addressing unmet medical needs in several cancer types, which collectively contribute to a favorable outlook for the company's stock.
Bears say
Elevation Oncology faces significant financial challenges that contribute to a negative outlook on its stock. The company's inability to access capital could disrupt its operations, impacting the timeline for achieving profitability and cash flow generation. Furthermore, the recent Phase 1 trial results for EO-3021 demonstrated efficacy primarily in a subset of patients, raising concerns about the broader market potential and contributing to unfavorable perceptions among investors, especially in light of the lack of revenue reported in 4Q24 and a net loss that was better than estimates but still indicative of ongoing financial strain.
This aggregate rating is based on analysts' research of Elevation Oncology and is not a guaranteed prediction by Public.com or investment advice.
Elevation Oncology (ELEV) Analyst Forecast & Price Prediction
Start investing in Elevation Oncology (ELEV)
Order type
Buy in
Order amount
Est. shares
0 shares